More Positive Amarin Developments This Week

While multiple followers have emailed me about some comments by someone named Jeerio re: FDA allowing JELIS data to be included when marketing Vascepa, I have no information to contribute whether that is fact or fiction. While it would seem positive, I would tread carefully with that information.

I will say I have been able to confirm that Vascepa will have expanded label data by end of this year, based on enrollment >50% for Reduce-It. This is very significant and if WallStreet actually got their heads out of their bums, the stock would trade up $3-5 on this expectation alone...